KRAS and lung cancer: Loss of either Rb1 or Cdkn2A accelerated lung cancer progression initiated by Kras/Trp53 mutation, consistent with the higher frequency of CDKN2A alteration in KRAS versus EGFR initiated human lung adenocarcinoma.